BackFirst Wave BioPharma Overview

First Wave BioPharma Minority Interest

First Wave BioPharma's minority interest is $4.8M.

Get informed when a big investor buys or sells

+ Follow
Minority Interest
$4.79M

Peer trimmed avg / median

Loading

First Wave BioPharma Minority Interest History

Loading

First Wave BioPharma vs. peers: Minority Interest Comparison

Loading

First Wave BioPharma Minority Interest Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

First Wave BioPharma (FWBI) FAQ

First Wave BioPharma's minority interest stands at $4.8M as of June 2026. In the prior-year period, the figure was $0. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

First Wave BioPharma reported $4.8M in minority interest versus $0 a year earlier. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

In the prior-year period, the figure was $0. Sustained growth in minority interest can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how First Wave BioPharma's minority interest evolved across reporting periods, while the comparison chart places FWBI next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, minority interest is commonly used to spot outliers. First Wave BioPharma's reading of $4.8M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.